
|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approach
by Karl Bayer, Monika Cserjan-Puschmann, Reingard Grabherr, Gerald Striedner, and Franz Clementschitsch, Institute of Applied Microbiology, Vienna, Austria A new strategy for controlling recombinant gene expression improves efficiency, maximizes host vector exploitation, reduces costs, improves product consistency, and accelerates product development. Continuous feeds of limited amounts of inducer proportional to biomass growth grant optimal control over the ratio between gene expression and host cell metabolism, providing stable, prolonged recombinant protein production.
Advertisement
Articles in this issue
over 24 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveover 24 years ago
Knowledge Management: The Four Pillars of Successover 24 years ago
Inside Washington: One Hundred Years of Biotech Regulationover 24 years ago
Guest Editorial: Supreme Court Rules on FestoAdvertisement
Related to this article

Merck and Kelun’s sac-TMT extends overall survival in pretreated endometrial cancer, Bristol Myers Squibb reports interim data and a patient death in its phase 1 CAR-T trial in multiple sclerosis, and BioNTech and DualityBio’s HER2 ADC meets its phase 3 goal but with limited expected benefit.

This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.

Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.

Full Phase 3 TroFuse-005 data presented at ESMO 2026 show the TROP2-directed ADC sacituzumab tirumotecan cut the risk of death by 32% vs chemotherapy, and an FDA decision is expected by June 2027.

A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.

BioNTech and DualityBio's HER2-directed ADC modestly improved progression-free survival over chemotherapy in DYNASTY-Breast02, but higher interstitial lung disease rates and an established competitor limit its potential in this setting.

Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team is making antibody manufacturing more efficient and replacing costly raw materials to cut monoclonal antibody costs to about $10 per gram.
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
5

